237 filings
8-K
MDCO
Medicines Co
6 Jan 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:30pm
8-K
MDCO
Medicines Co
6 Jan 20
Entry into a Material Definitive Agreement
12:28pm
8-K
MDCO
Medicines Co
25 Nov 19
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 billion
6:35am
8-K
MDCO
Medicines Co
30 Oct 19
The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran
7:18am
8-K
MDCO
Medicines Co
24 Jul 19
The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program
7:06am
8-K
p7kfzkwo
28 Jun 19
The Medicines Company Announces Pricing of Public Offering of Common Stock
4:42pm
8-K
onqrs6t
5 Jun 19
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
p5xk4apyqpkarly 4u
25 Apr 19
The Medicines Company Reports First-Quarter 2019 Financial Results and Significant Progress with the Inclisiran Clinical Development Program
7:59am
8-K
290p gurkyfxxx
18 Mar 19
Departure of Directors or Certain Officers
4:51pm
8-K
6ax5l3zkl05ljjj
27 Feb 19
The Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial Results
7:58am
8-K
hxhnjbgb bm8tctvbpmm
14 Jan 19
Other Events
4:09pm
8-K
mioa9xm 6o
4 Jan 19
Other Events
4:06pm
8-K
v4iqyufltu gs4
18 Dec 18
Entry into a Material Definitive Agreement
4:07pm
8-K
2i37 taobuf
14 Dec 18
Other Events
6:05am
8-K
0m9zcb
12 Dec 18
Risks Related to Development, Approval and Commercialization of Inclisiran
5:29pm
8-K
lcuq vlglyk788
12 Dec 18
The Medicines Company Announces Intention to Offer $150 Million of Convertible Notes
5:23pm
8-K
8ru1cub vs8s
11 Dec 18
The Medicines Company Appoints Mark Timney as Chief Executive Officer
5:19pm
8-K
6334x 5qobvi
8 Nov 18
Results of Operations and Financial Condition
8:16am
8-K
dvxktk
28 Aug 18
Departure of Directors or Certain Officers
12:00am
8-K
xot fxmgrlwz2sc
1 Aug 18
Results of Operations and Financial Condition
8:12am